ArticleJournal of bone oncology2019

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.

Peyman Hadji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.